Trials / Withdrawn
WithdrawnNCT00380835
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amrubicin |
Timeline
- Completion
- 2007-12-01
- First posted
- 2006-09-27
- Last updated
- 2008-09-23
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00380835. Inclusion in this directory is not an endorsement.